Systemic inflammatory response to predict clinical outcome in patients with resected pancreatic cancer treated with adjuvant gemcitabine monotherapy.

223 Background: Systemic inflammatory response (SIR) has been shown to associate with poor outcome in either inoperable or operable pancreatic cancer. However, whether the presence of a SIR predicts poor clinical outcome of pancreatic cancer patients in adjuvant setting is unclear. The aim of present study was to determine the relationship between SIR, as evaluated by Modified Glasgow prognostic score (mGPS), and outcome of pancreatic cancer patients treated with adjuvant chemotherapy. Methods: A total of 42 resected pancreatic cancer patients were analyzed for mGPS before adjuvant gemcitabine chemotherapy. The mGPS was constructed as follows: patients with both an elevated C-reactive protein (> 0.3mg/dl) and hypoalbuminaemia (< 3.5mg/dl) were allocated a score of 2. Patients with one or none of these abnormalities were allocated a score of 1or 0, respectively. Results: There were 25 patients assigned to score 0, 12 patients to score 1, and 5 patients to score 2. The median OS in patients with score 0, score 1, and score 2 were 23.9 months, 10.3 months, and 9.9 months, respectively. The DFS in patients with score 0, score 1, and score 2 were 11.0 months, 5.9 months, and 3.6 months, respectively. The OS and DFS after surgery of the patients with SIR (score 1 and 2) were significantly poorer than that of the patients with score 0 (P=0.0278 for OS, P=0.0011 for DFS by log-rank test). Conclusions: The presence of SIR, as evaluated by Modified Glasgow prognostic score (mGPS), predicts poor clinical outcome in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.

Download Full-text

Correlation between Prognostic Nutritional Index, Glasgow Prognostic Score, Systemic Inflammatory Response, and TNM Staging in Colorectal Cancer Patients

Nutrition and Cancer ◽

10.1080/01635581.2019.1675725 ◽

2019 ◽

Vol 72 (7) ◽

pp. 1170-1177

Author(s):

Xuejing Bai ◽

Lei Feng

Keyword(s):

Colorectal Cancer ◽

Inflammatory Response ◽

Cancer Patients ◽

Prognostic Score ◽

Glasgow Prognostic Score ◽

Prognostic Nutritional Index ◽

Tnm Staging ◽

Systemic Inflammatory Response ◽

Nutritional Index ◽

Colorectal Cancer Patients

Download Full-text

The Prognostic Value of Modified Glasgow Prognostic Score in Pancreatic Cancer: A Meta-analysis

10.21203/rs.3.rs-47891/v1 ◽

2020 ◽

Author(s):

Huan Zhang ◽

Dianyun Ren ◽

Xin Jin ◽

Heshui Wu

Keyword(s):

Pancreatic Cancer ◽

Cancer Patients ◽

Prognostic Value ◽

Close Association ◽

Meta Analysis ◽

Prognostic Score ◽

Prognostic Significance ◽

Glasgow Prognostic Score ◽

Cochrane Library ◽

Modified Glasgow Prognostic Score

Abstract Background: Several studies were conducted to explore the prognostic value of modified Glasgow Prognostic Score (mGPS) in pancreatic cancer, which reported contradictory results. The purpose of this meta-analysis was to summarize the prognostic value of mGPS in pancreatic cancer by investigating the correlation between mGPS and overall survival (OS). Methods: A systematic literature search was performed in PubMed, EMBASE, ISI Web of Science, Cochrane library databases and OVID to identify eligible studies published from Jan 1, 2011 to June 20, 2020. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were used to detect the prognostic significance of mGPS in patients with pancreatic cancer. Results: A total of 222 non-repetitive studies were identified, and 20 enrolled studies described the association between survival outcomes and mGPS in pancreatic cancer patients. The results showed a significant correlation between high mGPS and poor OS (HR=1.50, 95% CI=1.20–1.89, P<0.0001). Similar results were observed in the subgroup analyses of OS, which were based on the treatment regimen and research region. Conclusions: Our study suggested the close association between the poor prognosis and high level of mGPS, which will be helpful for future clinical applications in pancreatic cancer patients.

Download Full-text

High calpain-1 expression predicts a poor clinical outcome and contributes to tumor progression in pancreatic cancer patients

Clinical & Translational Oncology ◽

10.1007/s12094-018-02006-6 ◽

2018 ◽

Vol 21 (7) ◽

pp. 924-932 ◽

Cited By ~ 3

Author(s):

L. M. Yu ◽

Y. S. Zhu ◽

C. Z. Xu ◽

L. L. Zhou ◽

Z. X. Xue ◽

...

Keyword(s):

Pancreatic Cancer ◽

Clinical Outcome ◽

Tumor Progression ◽

Cancer Patients ◽

Poor Clinical Outcome

Download Full-text

Modified Glasgow prognostic score can predict survival of muscle invasive bladder cancer patients after radiotherapy

Journal of Radiation Research ◽

10.1093/jrr/rraa039 ◽

2020 ◽

Vol 61 (4) ◽

pp. 616-621

Author(s):

Koyo Kikuchi ◽

Ryuji Nakamura ◽

Takafumi Segawa ◽

Hirobumi Oikawa ◽

Hisanori Ariga

Keyword(s):

Bladder Cancer ◽

Cancer Patients ◽

Prognostic Score ◽

Glasgow Prognostic Score ◽

Invasive Bladder Cancer ◽

Muscle Invasive Bladder Cancer ◽

Cox Regression Analysis ◽

Modified Glasgow Prognostic Score ◽

Kaplan Meier ◽

Muscle Invasive

Abstract In patients with various cancers, modified Glasgow prognostic score (mGPS) before treatment has predicted prognoses after antitumor therapy. This study aimed to assess whether pretreatment mGPS also has predictive value in patients with muscle-invasive bladder cancer (MIBC) after radiotherapy. A retrospective review accumulated 98 consecutive MIBC patients treated with definitive 3D-conformal radiotherapy from January 2011 to December 2016 in a single center. It included cT2-4bN0-3M0 patients with a median age of 79 years (range: 49 to 95 years). Radiotherapy was delivered at 60–66 Gy for bladder cancer. Patients were categorized in terms of their pretreatment serum albumin and C-reactive protein (CRP) values as mGPS_0, mGPS_1, and mGPS_2. Among them, cumulative overall survival (OS) rates were compared by Kaplan–Meier plots with log-rank tests. The number of patients with mGPS_0, mGPS_1, and mGPS_2 were 40, 40, and 18, respectively. The median follow-up time for all patients was 19 months (range: 2–73 months). The 2-year OS rate for all patients was 75.7%. The 2-year OS rates for mGPS_0, mGPS_1, and mGPS_2 were 85.1%, 71.3%, and 60.9%, respectively. Kaplan–Meier curves revealed a significantly higher cumulative OS rate for mGPS_0 compared with mGPS_1 and mGPS_2 (P = 0.003). Using multivariate Cox regression analysis, mGPS_0 and good performance status were associated with favorable OS rates, of which mGPS_0 was more significant (Hazard ratio 2.74, 95% CI 1.30–5.57, P = 0.008). Modified Glasgow prognostic score may be a novel biomarker that can predict survival in patients with MIBC after radiotherapy.

Download Full-text

The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis

Cancer Cell International ◽

10.1186/s12935-020-01558-4 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Huan Zhang ◽

Dianyun Ren ◽

Xin Jin ◽

Heshui Wu

Keyword(s):

Pancreatic Cancer ◽

Prognostic Value ◽

Close Association ◽

Meta Analysis ◽

Prognostic Score ◽

Prognostic Significance ◽

Glasgow Prognostic Score ◽

Cochrane Library ◽

Modified Glasgow Prognostic Score ◽

High Level

Abstract Background Several studies were conducted to explore the prognostic value of modified Glasgow Prognostic Score (mGPS) in pancreatic cancer, which reported contradictory results. The purpose of this meta-analysis was to summarize and further investigate the correlation between mGPS and overall survival (OS) in pancreatic cancer. Methods A systematic literature search was performed in PubMed, EMBASE, ISI Web of Science, Cochrane library databases and OVID to identify eligible studies published from Jan 1, 2011 to June 20, 2020. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were used to detect the prognostic significance of mGPS in patients with pancreatic cancer. Results A total of 222 non-repetitive studies were identified, and 20 related studies that explored the association between survival outcomes and mGPS in pancreatic cancer patients were finally enrolled in this meta-analysis. The results showed a significant correlation between high level of mGPS and poor OS (HR = 1.50, 95% CI 1.20–1.89, P < 0.0001). Similar results were observed in the subgroup analyses based on the treatment regimen and research region. Conclusions Our study suggested the close association between poor prognosis and high level of mGPS, which will be helpful for future clinical applications in patients with pancreatic cancer.

Download Full-text

Prognostic value of modified Glasgow Prognostic Score (mGPS) and neutrophil-lymphocyte ration (NLR) after curative resection for gastric cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.4_suppl.295 ◽

2020 ◽

Vol 38 (4_suppl) ◽

pp. 295-295

Author(s):

Yusuke Shimodaira ◽

Sachie Koike ◽

Yusuke Takahashi ◽

Masao Okada ◽

Kaori Hayashibara ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Prognostic Value ◽

Curative Resection ◽

Prognostic Score ◽

Glasgow Prognostic Score ◽

Rank Test ◽

Independent Predictive Factor ◽

Gastric Cancer Patients

295 Background: Several biomarkers based on serum chemistry have been reported to be associated with the prognosis of several types of cancers. This retrospective study aimed to investigate the prognostic value of preoperative mGPS and NLR after curative resection for gastric cancer. Methods: A total of 295 patients who underwent curative gastrectomy for primary gastric cancer at our institution from January 2013 to December 2017 were enrolled in this study. The mGPS was calculated by CRP and Alb using standard thresholds ( > 0.5 mg/dL for CRP and < 3.5 g/dL for Alb). The NLR was defined as absolute neutrophil count divided by absolute lymphocyte count. The survival curves of patients stratified by each parameter were plotted by the Kaplan-Meier method and compared by log-rank test. Multivariate Cox proportional hazards regression models were used to select parameters independently correlated with prognosis. Results: The median follow-up time was 36.7 months, and 29 patients died during follow-up. The estimated 5-year survival rate was 83.1%. Results from the univariate analyses showed mGPS2 (CRP > 0.5 mg/dL and Alb < 3.5 g/dL) was associated with poor survival while NLR and NLRc was not (P < 0.001, P = 0.506, and P = 0.423, respectively). In the multivariate analyses, the mGPS2 was identified as an independent predictive factor for OS in gastric cancer patients after curative resection (HR: 2.624; 95% CI: 1.058-6.505; P = 0.037). Conclusions: Preoperative mGPS2 was associated with worse survival after curative resection of gastric cancer patients. Based on our study, those with mPGS2 may be warranted to receive additional therapy or nutritional support to acquire better survival.

Download Full-text